Mirum Pharmaceuticals (MIRM) FCF Margin (2021 - 2026)

Mirum Pharmaceuticals' FCF Margin history runs 6 years deep, the most recent figure standing at 143.5% for Q1 2026.

• In Q1 2026, FCF Margin fell 14170.0% year-over-year to 143.5%; the TTM figure through Mar 2026 stood at 30.29% (down 2822.0% YoY), while the FY2025 annual figure was 10.53%, up 776.0% from the prior year.
• FCF Margin for Q1 2026 stood at 143.5%, down from 3.67% in the prior quarter.
• The five-year high for FCF Margin was 29.69% in Q3 2025, with the low at 307.7% in Q1 2022.
• The 5-year median for FCF Margin is 23.89% (2023), against an average of 55.35%.
• The sharpest annual moves came in 2022 and 2026: FCF Margin soared 93273 bps in 2022, then slumped 14170 bps in 2026.
• Mirum Pharmaceuticals' FCF Margin stood at 123.67% in 2022, then soared by 81 bps to 23.89% in 2023, then soared by 79 bps to 5.12% in 2024, then surged by 172 bps to 3.67% in 2025, then tumbled by 4009 bps to 143.5% in 2026.
• Business Quant data shows MIRM's FCF Margin at 143.5% in Q1 2026, 3.67% in Q4 2025, and 29.69% in Q3 2025.